Surgery and immunotherapy for returning ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- Your ovarian, fallopian tube, or primary peritoneal cancer has returned, and it responded well to your last chemotherapy (at least 6 months before it came back).
- Your cancer is not BRCA-mutated (a genetic change) and you have not had immunotherapy before.
- You have a specific biomarker called PD-L1 or enough CD8+ immune cells in your tumor.
- Your doctor believes all visible cancer can be removed with surgery.
- You are generally healthy enough for surgery and treatment (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
This study tests a combination of two drugs — a chemotherapy called liposomal irinotecan and an immunotherapy drug called enlonstobart — for women whose ovarian cancer has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.